{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:39:34Z","timestamp":1757612374672,"version":"3.44.0"},"reference-count":66,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>This study aimed to evaluate the pharmacological effects of haloperidol on the antinociceptive effects of buprenorphine and tramadol in rats. Dose\u2013response curves were constructed for the individual administration of haloperidol, buprenorphine, and tramadol in rats subjected to the formalin (1%) test. All the compounds demonstrated dose-dependent antinociceptive effects when administered individually. Pharmacological interactions were assessed using an isobolographic method. The doses required to achieve 50% of the maximal antinociceptive effect (ED<jats:sub>50<\/jats:sub>) for each drug were combined at a fixed 1\u2005:\u20051 ratio to establish a combination series of haloperidol + buprenorphine and haloperidol + tramadol. The results showed that buprenorphine achieved a higher maximal antinociceptive effect (98%) compared with tramadol (85%) and haloperidol (84.9%) when administered individually. Isobolographic analysis revealed that the experimental values (<jats:italic toggle=\"yes\">Z<\/jats:italic>\n                           <jats:sub>exp<\/jats:sub>) for haloperidol + buprenorphine (<jats:italic toggle=\"yes\">Z<\/jats:italic>\n                           <jats:sub>add<\/jats:sub> = 27.6\u2005\u00b1\u20055.5 vs. <jats:italic toggle=\"yes\">Z<\/jats:italic>\n                           <jats:sub>exp<\/jats:sub>\u2005=\u20055.47\u2005\u00b1\u20051.2) and haloperidol + tramadol (<jats:italic toggle=\"yes\">Z<\/jats:italic>\n                           <jats:sub>add<\/jats:sub> = 4987.68\u2005\u00b1\u2005651.5 vs. <jats:italic toggle=\"yes\">Z<\/jats:italic>\n                           <jats:sub>exp<\/jats:sub>\u2005=\u20051678.23\u2005\u00b1\u200589.8) were significantly lower than the theoretical values (<jats:italic toggle=\"yes\">Z<\/jats:italic>\n                           <jats:sub>add<\/jats:sub>), indicating synergistic interactions. On the basis of the experimental data, haloperidol potentiated the antinociception in the following order: haloperidol + buprenorphine, followed by haloperidol + tramadol. These findings suggest that such drug combinations could have potential applications in the ongoing research of treatments for chronic pain, depression-related pain, and cancer-associated pain.<\/jats:p>","DOI":"10.1097\/fbp.0000000000000852","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T11:00:11Z","timestamp":1756983611000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Haloperidol potentates the antinociceptive effect of buprenorphine and tramadol in rats"],"prefix":"10.1097","author":[{"given":"Rolffy","family":"Ortiz-Andrade","sequence":"first","affiliation":[{"name":"Laboratorio de Farmacolog\u00eda, Facultad de Qu\u00edmica, Universidad Aut\u00f3noma de Yucat\u00e1n, M\u00e9rida, Yucat\u00e1n, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilian Dolores","family":"Chel-Guerrero","sequence":"additional","affiliation":[{"name":"Laboratorio de Farmacolog\u00eda, Facultad de Qu\u00edmica, Universidad Aut\u00f3noma de Yucat\u00e1n, M\u00e9rida, Yucat\u00e1n, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myrna","family":"D\u00e9ciga-Campos","sequence":"additional","affiliation":[{"name":"Secci\u00f3n de Estudios de Posgrado e Investigaci\u00f3n, Escuela Superior de Medicina, Instituto Polit\u00e9cnico Nacional, Mexico City, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"R1-20250904","first-page":"51","article-title":"Behavioral and pharmacokinetic interaction between morphine and haloperidol in the rat.","volume":"36","author":"Adamus","year":"1984","journal-title":"Pol J Pharmacol Pharm"},{"key":"R2-20250904","first-page":"63","article-title":"Pharmacologic therapy for acute pain.","volume":"104","author":"Amaechi","year":"2021","journal-title":"Am Fam Physician"},{"key":"R3-20250904","doi-asserted-by":"crossref","first-page":"101","DOI":"10.21315\/mjms2017.24.5.11","article-title":"Sample size calculation in animal studies using resource equation approach.","volume":"24","author":"Arifin","year":"2017","journal-title":"Malays J Med Sci"},{"key":"R4-20250904","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.3390\/cells12162028","article-title":"Sexual dimorphism in the mechanism of pain central sensitization.","volume":"12","author":"Barcelon","year":"2023","journal-title":"Cells"},{"key":"R5-20250904","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0014-2999(02)02274-4","article-title":"Sex-related differences in mechanical nociception and antinociception produced by mu- and kappa-opioid receptor agonists in rats.","volume":"452","author":"Barrett","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"R6-20250904","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0196-9781(00)00252-7","article-title":"Agonistic effects of the opioid buprenorphine on the nociceptin\/OFQ receptor.","volume":"21","author":"Bloms-Funke","year":"2000","journal-title":"Peptides"},{"key":"R7-20250904","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0014-2999(90)90260-D","article-title":"Metabolites of haloperidol display preferential activity at sigma receptors compared to dopamine D-2 receptors.","volume":"177","author":"Bowen","year":"1990","journal-title":"Eur J Pharmacol"},{"key":"R8-20250904","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00213-005-0127-z","article-title":"Antinociceptive effects of haloperidol and its metabolites in the formalin test in mice.","volume":"182","author":"Cend\u00e1n","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"R9-20250904","first-page":"58","article-title":"[Effect of haloperidol on the analgesic activity of opiate agonists administered intracisternally and intrathecally].","volume":"48","author":"Chichenkov","year":"1985","journal-title":"Farmakol Toksikol"},{"key":"R10-20250904","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/S0022-3565(25)24045-9","article-title":"Selective antagonism of opioid analgesia by a sigma system.","volume":"271","author":"Chien","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"R11-20250904","first-page":"275P","article-title":"The effect of acute doses of buprenorphine on concentrations of homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA) and 3-methoxy-4-hydroxyphenylglycol (MHPG) in the rat forebrain [proceedings].","volume":"58","author":"Cowan","year":"1976","journal-title":"Br J Pharmacol"},{"key":"R12-20250904","first-page":"141","article-title":"Characterizing the role of haloperidol for analgesia in the Emergency Department.","volume":"12","author":"Cowling","year":"2019","journal-title":"J Pain Manag"},{"key":"R13-20250904","doi-asserted-by":"crossref","first-page":"26323524241266603","DOI":"10.1177\/26323524241266603","article-title":"Novel drug treatments for pain in advanced cancer and serious illness: a focus on neuropathic pain and chemotherapy-induced peripheral neuropathy.","volume":"18","author":"Davis","year":"2024","journal-title":"Palliat Care Soc Pract"},{"key":"R14-20250904","doi-asserted-by":"crossref","first-page":"173702","DOI":"10.1016\/j.ejphar.2020.173702","article-title":"Synergistic interaction between haloperidol and gabapentin in a model of neuropathic nociception in rat.","volume":"891","author":"D\u00e9ciga-Campos","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"R15-20250904","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/0028-3908(85)90186-8","article-title":"Effects of haloperidol on morphine-induced antinociception morphine tolerance and withdrawal in hyperprolactinaemic rats.","volume":"24","author":"Drago","year":"1985","journal-title":"Neuropharmacology"},{"key":"R16-20250904","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0304-3959(77)90130-0","article-title":"The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats.","volume":"4","author":"Dubuisson","year":"1977","journal-title":"Pain"},{"key":"R17-20250904","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.pain.2007.08.033","article-title":"Pharmacologic management of neuropathic pain: evidence-based recommendations.","volume":"132","author":"Dworkin","year":"2007","journal-title":"Pain"},{"key":"R18-20250904","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2044.1979.tb06339.x","article-title":"Relief of pain after surgery. A comparison of sublingual buprenorphine and intramuscular papaveretum.","volume":"34","author":"Fry","year":"1979","journal-title":"Anaesthesia"},{"key":"R19-20250904","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/BF02247468","article-title":"Effects of morphine, naloxone, buprenorphine, butorphanol, haloperidol and imipramine on morphine withdrawal signs in cynomolgus monkeys.","volume":"116","author":"Fukase","year":"1994","journal-title":"Psychopharmacology (Berl)"},{"key":"R20-20250904","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0006-8993(02)03661-2","article-title":"The role of sex hormones on formalin-induced nociceptive responses.","volume":"958","author":"Gaumond","year":"2002","journal-title":"Brain Res"},{"key":"R21-20250904","first-page":"85","article-title":"Effectiveness and safety of haloperidol add-on methadone in acute opium withdrawal symptoms of opioid-dependent patients: a double-blind randomized placebo-controlled clinical trial.","volume":"13","author":"Ghaderi-Bafti","year":"2021","journal-title":"Addict Health"},{"key":"R22-20250904","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/ADM.0000000000001189","article-title":"Evidence on buprenorphine dose limits: a review.","volume":"17","author":"Grande","year":"2023","journal-title":"J Addict Med"},{"key":"R23-20250904","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200443130-00004","article-title":"Clinical pharmacology of tramadol.","volume":"43","author":"Grond","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"R24-20250904","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/AJP.0b013e31815ca2b4","article-title":"Buprenorphine: new tricks with an old molecule for pain management.","volume":"24","author":"Heit","year":"2008","journal-title":"Clin J Pain"},{"key":"R25-20250904","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1023\/A:1008771621812","article-title":"Stability of buprenorphine, haloperidol and glycopyrrolate mixture in a 0.9% sodium chloride solution.","volume":"21","author":"J\u00e4ppinen","year":"1999","journal-title":"Pharm World Sci"},{"key":"R26-20250904","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jpainsymman.2004.07.005","article-title":"Buprenorphine: considerations for pain management.","volume":"29","author":"Johnson","year":"2005","journal-title":"J Pain Symptom Manage"},{"key":"R27-20250904","first-page":"209","article-title":"Acute tramadol-induced cellular tolerance and dependence of ventral tegmental area dopaminergic neurons: an in vivo electrophysiological study.","volume":"10","author":"Khodayari","year":"2019","journal-title":"Basic Clin Neurosci"},{"key":"R28-20250904","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1097\/JCP.0b013e31823657d9","article-title":"A review and Bayesian meta-analysis of clinical efficacy and adverse effects of 4 atypical neuroleptic drugs compared with haloperidol and placebo.","volume":"31","author":"Klemp","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"R29-20250904","doi-asserted-by":"crossref","first-page":"623","DOI":"10.5811\/westjem.2021.2.50390","article-title":"Study of haloperidol for abdominal pain in the emergency department (SHAPE).","volume":"22","author":"Knudsen-Lachendro","year":"2021","journal-title":"West J Emerg Med"},{"key":"R30-20250904","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/jso.20359","article-title":"The molecular biology of esophageal adenocarcinoma.","volume":"92","author":"Koppert","year":"2005","journal-title":"J Surg Oncol"},{"key":"R31-20250904","first-page":"37","article-title":"The ambulation-increasing effect of buprenorphine in mice: comparison with the effect of morphine.","volume":"26","author":"Kuribara","year":"1991","journal-title":"Arukoru Kenkyuto Yakubutsu Ison"},{"key":"R32-20250904","doi-asserted-by":"crossref","first-page":"145","DOI":"10.36076\/ppj.2011\/14\/145","article-title":"A comprehensive review of opioid-induced hyperalgesia.","volume":"14","author":"Lee","year":"2011","journal-title":"Pain Physician"},{"key":"R33-20250904","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1124\/jpet.112.199851","article-title":"Sex, pain, and opioids: interdependent influences of sex and pain modality on dynorphin-mediated antinociception in rats.","volume":"344","author":"Liu","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"R34-20250904","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1056\/NEJMra1800222","article-title":"Opioid tolerance in critical illness.","volume":"380","author":"Martyn","year":"2019","journal-title":"N Engl J Med"},{"key":"R35-20250904","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0014-2999(00)00430-1","article-title":"Correlation between neuroleptic binding to sigma(1) and sigma(2) receptors and acute dystonic reactions.","volume":"401","author":"Matsumoto","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"R36-20250904","doi-asserted-by":"crossref","first-page":"173825","DOI":"10.1016\/j.ejphar.2020.173825","article-title":"Haloperidol potentiates antinociceptive effects of morphine and disrupt opioid tolerance.","volume":"893","author":"Mena-Vald\u00e9s","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"R37-20250904","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s40263-019-00660-0","article-title":"Opioid-induced tolerance and hyperalgesia.","volume":"33","author":"Mercadante","year":"2019","journal-title":"CNS Drugs"},{"key":"R38-20250904","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/978-3-319-50174-1_8","article-title":"Pharmacological modulation of the sigma 1 receptor and the treatment of pain.","volume":"964","author":"Merlos","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"R39-20250904","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00210-015-1167-5","article-title":"What is the main mechanism of tramadol?","volume":"388","author":"Minami","year":"2015","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"R40-20250904","doi-asserted-by":"crossref","first-page":"104232","DOI":"10.1016\/j.lpm.2024.104232","article-title":"Neuropathic pain: evidence based recommendations.","volume":"53","author":"Moisset","year":"2024","journal-title":"Presse Med"},{"key":"R41-20250904","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ajem.2022.02.012","article-title":"Sub dissociative dose of ketamine with haloperidol versus fentanyl on pain reduction in patients with acute pain in the emergency department; a randomized clinical trial.","volume":"54","author":"Moradi","year":"2022","journal-title":"Am J Emerg Med"},{"key":"R42-20250904","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/j.1532-2149.2013.00346.x","article-title":"Sex differences in formalin-evoked primary afferent release of substance P.","volume":"18","author":"Nazarian","year":"2014","journal-title":"Eur J Pain"},{"key":"R43-20250904","first-page":"65","article-title":"Physical compatibility and in vivo evaluation of drug mixtures for subcutaneous infusion to cancer patients in palliative care.","volume":"10","author":"Negro","year":"2002","journal-title":"Support Care Cancer"},{"key":"R44-20250904","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jpainsymman.2005.02.011","article-title":"Stability of tramadol and haloperidol for continuous subcutaneous infusion at home.","volume":"30","author":"Negro","year":"2005","journal-title":"J Pain Symptom Manage"},{"key":"R45-20250904","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000343632","article-title":"Analgesic effects of tramadol in combination with adjuvant drugs: an experimental study in rats.","volume":"91","author":"Okulicz-Kozaryn","year":"2013","journal-title":"Pharmacology"},{"key":"R46-20250904","first-page":"e59837","article-title":"Bispecific sigma1R-antagonist\/MOR-agonist compounds for pain.","volume":"16","author":"Raffa","year":"2024","journal-title":"Cureus"},{"key":"R47-20250904","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13041-020-00676-4","article-title":"The sigma 2 receptor promotes and the sigma 1 receptor inhibits mu-opioid receptor-mediated antinociception.","volume":"13","author":"S\u00e1nchez-Bl\u00e1zquez","year":"2020","journal-title":"Mol Brain"},{"key":"R48-20250904","doi-asserted-by":"crossref","first-page":"201","DOI":"10.36076\/ppj.2008\/11\/201","article-title":"Combination opioid analgesics.","volume":"11","author":"Smith","year":"2008","journal-title":"Pain Physician"},{"key":"R49-20250904","first-page":"200","article-title":"Primary care management of opioid use disorders: abstinence, methadone, or buprenorphine-naloxone?","volume":"63","author":"Srivastava","year":"2017","journal-title":"Can Fam Physician"},{"key":"R50-20250904","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12864-019-5512-9","article-title":"Sex differences in gene regulation in the dorsal root ganglion after nerve injury.","volume":"20","author":"Stephens","year":"2019","journal-title":"BMC Genomics"},{"key":"R51-20250904","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/ejp.2234","article-title":"The costs of chronic pain-long-term estimates.","volume":"28","author":"Stubhaug","year":"2024","journal-title":"Eur J Pain"},{"key":"R52-20250904","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.biopha.2018.12.085","article-title":"An overview of tramadol and its usage in pain management and future perspective.","volume":"111","author":"Subedi","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"R53-20250904","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0304-3959(92)90193-F","article-title":"Statistical analysis of drug combinations for synergism.","volume":"49","author":"Tallarida","year":"1992","journal-title":"Pain"},{"key":"R54-20250904","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0022-3565(24)29450-7","article-title":"Drug synergism: its detection and applications.","volume":"298","author":"Tallarida","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"R55-20250904","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/978-1-4419-6306-2_17","article-title":"Combination analysis.","volume":"678","author":"Tallarida","year":"2010","journal-title":"Adv Exp Med Biol"},{"key":"R56-20250904","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/0024-3205(89)90148-3","article-title":"Statistical analysis of drug-drug and site-site interactions with isobolograms.","volume":"45","author":"Tallarida","year":"1989","journal-title":"Life Sci"},{"key":"R57-20250904","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/j.pain.0000000000001384","article-title":"Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11).","volume":"160","author":"Treede","year":"2019","journal-title":"Pain"},{"key":"R58-20250904","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00213-003-1626-4","article-title":"Reassessment of buprenorphine in conditioned place preference: temporal and pharmacological considerations.","volume":"172","author":"Tzschentke","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"R59-20250904","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3389\/fphar.2019.00223","article-title":"Allosteric modulators of sigma-1 receptor: a review.","volume":"10","author":"Vavers","year":"2019","journal-title":"Front Pharmacol"},{"key":"R60-20250904","doi-asserted-by":"crossref","first-page":"116524","DOI":"10.1016\/j.biopha.2024.116524","article-title":"Antinociceptive effect of LMH-2, a new sigma-1 receptor antagonist analog of haloperidol, on the neuropathic pain of diabetic mice.","volume":"174","author":"Ventura-Mart\u00ednez","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"R61-20250904","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/jnc.12768","article-title":"Mu-opioid receptor splice variants: sex-dependent regulation by chronic morphine.","volume":"130","author":"Verzillo","year":"2014","journal-title":"J Neurochem"},{"key":"R62-20250904","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1212\/WNL.38.6.961","article-title":"Evidence for a role of haloperidol-sensitive sigma-\u2018opiate\u2019 receptors in the motor effects of antipsychotic drugs.","volume":"38","author":"Walker","year":"1998","journal-title":"Neurology"},{"key":"R63-20250904","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1124\/jpet.110.175539","article-title":"Haloperidol disrupts opioid-antinociceptive tolerance and physical dependence.","volume":"338","author":"Yang","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"R64-20250904","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1016\/j.neuron.2024.09.014","article-title":"Central control of opioid-induced mechanical hypersensitivity and tolerance in mice.","volume":"112","author":"Yin","year":"2024","journal-title":"Neuron"},{"key":"R65-20250904","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejphar.2013.01.068","article-title":"Sigma 1 receptor: a new therapeutic target for pain.","volume":"716","author":"Zamanillo","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"R66-20250904","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0304-3959(83)90201-4","article-title":"Ethical guidelines for investigations of experimental pain in conscious animals.","volume":"16","author":"Zimmermann","year":"1983","journal-title":"Pain"}],"container-title":["Behavioural Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0000000000000852","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T11:00:51Z","timestamp":1756983651000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0000000000000852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":66,"URL":"https:\/\/doi.org\/10.1097\/fbp.0000000000000852","relation":{},"ISSN":["0955-8810","1473-5849"],"issn-type":[{"type":"print","value":"0955-8810"},{"type":"electronic","value":"1473-5849"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"assertion":[{"value":"2025-02-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}